近日，康诺亚发布 2025 上半年业绩公告，营收 4.99 亿元，同比暴增 812%，其中包括合作收入 3.29 亿元。研发支出 3.60 亿元，同比增长 9%。期内亏损为人民币7879.9万元，同比收窄77%；经调整期内亏损为人民币6263.4万元，同比收窄80%。目前，康诺亚已有 1 款产品获批上市，12 款产品处于临床阶段。康悦达（司普奇拜单抗）是国产首款获批的 IL-4R 抗体药物，自 ...
Source Link近日，康诺亚发布 2025 上半年业绩公告，营收 4.99 亿元，同比暴增 812%，其中包括合作收入 3.29 亿元。研发支出 3.60 亿元，同比增长 9%。期内亏损为人民币7879.9万元，同比收窄77%；经调整期内亏损为人民币6263.4万元，同比收窄80%。目前，康诺亚已有 1 款产品获批上市，12 款产品处于临床阶段。康悦达（司普奇拜单抗）是国产首款获批的 IL-4R 抗体药物，自 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.